Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a chatbot teach diabetes patients which herbal remedies are safe?

NCT ID NCT07835061

NEW Disease control Sponsor: Chang Gung University of Science and Technology Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 22, 2026 · Last updated Sep 22, 2026

Summary

Researchers are testing an AI chatbot designed to help people with diabetes understand complementary and integrative medicine, the herbs, supplements, and other therapies many patients use alongside standard care. The 12-week program delivers short videos, risk-benefit lessons, and links to government health websites. The trial enrolls 113 adults who have had diabetes for at least a year and have used complementary medicine for at least three months. Researchers measure whether participants better understand the benefits and risks of these therapies and whether they feel more in control of their diabetes.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an AI chatbot that teaches people with diabetes about complementary and integrative medicine
What this could lead to
If it works, this could give people with diabetes a simple digital tool to judge which complementary therapies are safe and which are risky. It could also point toward chatbot-based education for other long-term conditions.
What could go wrong
This is a small, single-country study of 113 people, so any benefit may not hold up in larger or more diverse groups. Chatbot advice can also be wrong or misunderstood, and people may not stick with a 12-week program.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 113 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2026

Expected to finish

Jul 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

20 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * People over the age of 20 * diagnosis of diabetes at least 12 months before the interview; and * The use of CAM at least 3 months * Sufficient mental ability to understand the informed consent form and sign it. Exclusion Criteria: * Participants will be excluded by an assistant researcher if they serious physical condition and hard of hearing and seeing.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus Empowerment

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes

Contacts and locations

Locations

  • Cheng Gung Memorial Hospital

    Linkou District, Taoyuan City,, Guishan District 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.